These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31784984)

  • 1. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
    Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
    Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HIF-1α Knockout Primary Human Natural Killer Cells Including Populations in Allogeneic Glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Yamada K; Matsuda R; Nakamura M; Nishimura F; Yamada S; Park YS; Tsujimura T; Nakagawa I
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.
    Shaim H; Shanley M; Basar R; Daher M; Gumin J; Zamler DB; Uprety N; Wang F; Huang Y; Gabrusiewicz K; Miao Q; Dou J; Alsuliman A; Kerbauy LN; Acharya S; Mohanty V; Mendt M; Li S; Lu J; Wei J; Fowlkes NW; Gokdemir E; Ensley EL; Kaplan M; Kassab C; Li L; Ozcan G; Banerjee PP; Shen Y; Gilbert AL; Jones CM; Bdiwi M; Nunez-Cortes AK; Liu E; Yu J; Imahashi N; Muniz-Feliciano L; Li Y; Hu J; Draetta G; Marin D; Yu D; Mielke S; Eyrich M; Champlin RE; Chen K; Lang FF; Shpall EJ; Heimberger AB; Rezvani K
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34138753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image-based assessment of natural killer cell activity against glioblastoma stem cells.
    Du Y; Metcalfe S; Akunapuram S; Ghosh S; Spruck C; Richardson AM; Cohen-Gadol AA; Shen J
    FEBS Open Bio; 2024 Jun; 14(6):1028-1034. PubMed ID: 38740554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma.
    Nguyen TTT; Gao Q; Mun JY; Zhu Z; Shu C; Naim A; Rogava M; Izar B; Westhoff MA; Karpel-Massler G; Siegelin MD
    Cells; 2024 Jul; 13(13):. PubMed ID: 38995006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
    Dumas AA; Pomella N; Rosser G; Guglielmi L; Vinel C; Millner TO; Rees J; Aley N; Sheer D; Wei J; Marisetty A; Heimberger AB; Bowman RL; Brandner S; Joyce JA; Marino S
    EMBO J; 2020 Aug; 39(15):e103790. PubMed ID: 32567735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
    Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
    J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
    Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
    Front Immunol; 2020; 11():835. PubMed ID: 32457755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of Glioblastoma Associated with Immune Checkpoints and Tumor Microenvironment based on Immunogenomic Profiling.
    Zheng P; Zhang X; Ren D; Bai Q
    Neurol India; 2024 Mar; 72(2):297-303. PubMed ID: 38691473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.
    Gangoso E; Southgate B; Bradley L; Rus S; Galvez-Cancino F; McGivern N; Güç E; Kapourani CA; Byron A; Ferguson KM; Alfazema N; Morrison G; Grant V; Blin C; Sou I; Marques-Torrejon MA; Conde L; Parrinello S; Herrero J; Beck S; Brandner S; Brennan PM; Bertone P; Pollard JW; Quezada SA; Sproul D; Frame MC; Serrels A; Pollard SM
    Cell; 2021 Apr; 184(9):2454-2470.e26. PubMed ID: 33857425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression.
    Lu IN; Dobersalske C; Rauschenbach L; Teuber-Hanselmann S; Steinbach A; Ullrich V; Prasad S; Blau T; Kebir S; Siveke JT; Becker JC; Sure U; Glas M; Scheffler B; Cima I
    Nat Commun; 2021 Jun; 12(1):3895. PubMed ID: 34162860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma.
    Safaee MM; Wang EJ; Jain S; Chen JS; Gill S; Zheng AC; Garcia JH; Beniwal AS; Tran Y; Nguyen AT; Trieu M; Leung K; Wells J; Maclean JM; Wycoff K; Aghi MK
    Sci Rep; 2022 Jan; 12(1):1464. PubMed ID: 35087132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.